(Q42115204)

16 October 2017

Strong emerging rationale for combining oncogene-targeted agents with immunotherapy (English)

1 reference

16 October 2017

1 reference

3

Patrick Hwu

1 reference

16 October 2017

Yan Yang

1

1 reference

16 October 2017

Gregory Lizée

series ordinal

2

1 reference

16 October 2017

language of work or name

1 reference

1 February 2013

1 reference

16 October 2017

1 reference

16 October 2017

2

1 reference

16 October 2017

2

1 reference

16 October 2017

e22730

1 reference

Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.

16 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601155

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601155

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601155

The secret ally: immunostimulation by anticancer drugs

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601155

Exploiting antitumor immunity to overcome relapse and improve remission duration

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601155

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601155

Immunomodulatory effects of anti-angiogenic drugs

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601155

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601155

The stem cell factor receptor/c-Kit as a drug target in cancer

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601155

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3601155

17 August 2018

Identifiers

DOI

10.4161/ONCI.22730

1 reference

16 October 2017

1 reference

16 October 2017

PubMed publication ID

23524978

1 reference